好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Cerebellar infarcts are associated with a higher frequency of dementia and decreased performance in cognitive domains of memory, attention, and language.
Aging, Dementia, and Behavioral Neurology
P17 - Poster Session 17 (11:45 AM-12:45 PM)
3-001

To investigate the clinical associations between cerebellar infarcts and cognition in a population-based study.

Brain infarctions have been associated with future risk of stroke and clinical dementia. However, most studies have focused on the effect of anterior circulation infarcts on cognitive performance, whereas the role of infarcts in the cerebellum remains unclear. The objective of this study was to determine the relationship between cerebellar infarcts and cognition in a large normative population.

We retrospectively identified 46 participants from the Mayo Clinic Study of Aging with a single infarct located in the cerebellum as identified on a FLAIR MRI image. We compared demographic variables, cardiovascular risk factors, and performance on cognitive testing from this cohort against a normative population of participants from this study without any history of infarcts. Cognitive testing included nine measures assessing four domains: memory, attention, language, and visuospatial.

With respect to cardiovascular risk factors, participants with cerebellar infarcts had a higher frequency of diabetes (17.4 vs 15.2%), hypertension (69.9% vs 59,4%), hyperlipidemia (87.0% vs 79.4%), atrial fibrillation (15.2% vs 7.4%), atrial flutter (6.5% vs 2.3%), myocardial infarction (8.1% vs 13.0%), and coronary artery disease (26.1% vs 16.0%), but not smoking (41.3% vs 46.2%). The participants with cerebellar infarcts also had lower scores in the memory (-0.06 vs 0.05), attention (-0.34 vs 0.04), and language (-0.27 vs -0.02) domains but not in the visuospatial domain (0.17 vs 0.16). The frequency of dementia was higher in the group with cerebellar infarcts (4.3% vs 2.8%).

Our study found that the presence of infarcts in the cerebellum is associated with cardiovascular risk factors and a decline in cognitive performance. This evidence reinforces the possible role of the cerebellum in cognitive networks and its disruption in vascular lesions.

Authors/Disclosures
Camilo Bermudez, MD, PhD (Mayo Clinic)
PRESENTER 		Dr. Bermudez has nothing to disclose.
Sheela Raghavan No disclosure on file
Mary M. Machulda, PhD (Mayo Clinic) The institution of Dr. Machulda has received research support from NIH.
Scott Przybelski Scott Przybelski has nothing to disclose.
No disclosure on file
Timothy Lesnick No disclosure on file
David S. Knopman, MD, FAAN (Mayo Clinic) Dr. Knopman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for DIAN TU study. The institution of Dr. Knopman has received research support from NIH.
Ronald C. Petersen, MD, PhD, FAAN (Mayo Clinic) Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly and Co.. Dr. Petersen has received personal compensation in the range of $0-$499 for serving as a Consultant for Eisai, Inc.. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has a non-compensated relationship as a Board of Directors with American Brain Foundation that is relevant to AAN interests or activities.
Petrice M. Cogswell, MD, PhD Dr. Cogswell has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Cogswell has received personal compensation in the range of $5,000-$9,999 for serving as a Medical education speaker with Eisai. Dr. Cogswell has received personal compensation in the range of $500-$4,999 for serving as a Medical education speaker with Kaplan.
Michelle M. Mielke, PhD (Wake Forest University School of Medicine) Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for LabCorp. Dr. Mielke has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Siemens Healthineers. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sunbird Bio. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai. Dr. Mielke has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novo Nordisk.
Prashanthi Vemuri, PhD (Mayo Clinic) The institution of Dr. Vemuri has received research support from NIH.
Clifford R. Jack, Jr., MD (Mayo Clinic) The institution of Dr. Jack has received research support from NIH. The institution of Dr. Jack has received research support from Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic.
Jonathan Graff-Radford, MD, FAAN Dr. Graff-Radford has received personal compensation for serving as an employee of Mayo Clinic. Dr. Graff-Radford has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NINDS/NIH. Dr. Graff-Radford has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA Neurology. Dr. Graff-Radford has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Open evidence . The institution of Dr. Graff-Radford has received research support from NIH. The institution of Dr. Graff-Radford has received research support from Eisai. The institution of Dr. Graff-Radford has received research support from Cognition therapeutics. Dr. Graff-Radford has received personal compensation in the range of $5,000-$9,999 for serving as a Faculty Member with IMPACT AD .